Several generic drug manufacturers are accused of price-fixing in a lawsuit; the state of Washington offers residents a universally available public option for health insurance; bills proposed by states to limit vaccine exemptions have stalled.
On Friday, 44 states filed a lawsuit that accused several pharmaceutical companies of inflating prices on drugs and making efforts to prevent competition, The Hill reported Saturday. The suit claims that 20 drug manufacturers engaged in price-fixing and had illegally collaborated to divide up the market and increase prices by as much as 1000%. One company, Teva, which denied wrongdoing, was placed at the heart of the controversy and was accused of conspiring to raise prices of 86 drugs between July 2013 and January 2015.
The state of Washington has worked to make a public option for health insurance universally available for its residents, The New York Times reported. The plan was approved last month by state legislature and Governor Jay Inslee is expected to sign it into law today. Prices of a set of tiered plans, which would cover standard services, are expected to be 10% less expensive than comparable private insurance plans.
As the current measles outbreak has rapidly become the worst in decades, state legislatures have failed to limit exemptions that allow families to avoid vaccinating their children, according to The Pew Charitable Trusts. While states such as Arizona, Hawaii, Iowa, and New York had previously proposed bills to remove exemptions, they have either stalled in committee or failed to advance. The CDC has reported 764 measles infections in 23 states this year alone, far eclipsing numbers from recent years.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More